scholarly journals Silencing of long non-coding RNA MEG3 alleviates lipopolysaccharide-induced acute lung injury by acting as a molecular sponge of microRNA-7b to modulate NLRP3

Aging ◽  
2020 ◽  
Vol 12 (20) ◽  
pp. 20198-20211
Author(s):  
Handi Liao ◽  
Suning Zhang ◽  
Jianou Qiao
Keyword(s):  
Acute Lung Injury ◽  
Lung Injury ◽  
Non Coding Rna ◽  
Long Non Coding Rna

scholarly journals Long non-coding RNA (lncRNA): A potential therapeutic target in acute lung injury

2021 ◽  
Author(s):  
Almaz Zaki ◽  
M Shadab Ali ◽  
Vijay Hadda ◽  
Syed Mansoor Ali ◽  
Anita Chopra ◽  
...  
Keyword(s):  
Acute Lung Injury ◽  
Lung Injury ◽  
Therapeutic Target ◽  
Potential Therapeutic Target ◽  
Non Coding Rna ◽  
Long Non Coding Rna

Long non‐coding RNA MALAT1 sponges miR‐149 to promote inflammatory responses of LPS‐induced acute lung injury by targeting MyD88

2019 ◽  
Vol 44 (1) ◽  
pp. 317-326 ◽  
Author(s):  
Wei‐Jun Liang ◽  
Xiao‐Yuan Zeng ◽  
Sha‐Li Jiang ◽  
Hong‐Yi Tan ◽  
Mu‐Yun Yan ◽  
...  
Keyword(s):  
Acute Lung Injury ◽  
Lung Injury ◽  
Inflammatory Responses ◽  
Non Coding Rna ◽  
Long Non Coding Rna

scholarly journals Long non-coding RNA CHRF accelerates LPS-induced acute lung injury through microRNA-146a/Notch1 axis

2021 ◽  
Vol 9 (16) ◽  
pp. 1299-1299
Author(s):  
Shu Luo ◽  
Xuefeng Ding ◽  
Shiqiao Zhao ◽  
Tianyi Mou ◽  
Ruixiu Li ◽  
...  
Keyword(s):  
Acute Lung Injury ◽  
Lung Injury ◽  
Non Coding Rna ◽  
Long Non Coding Rna

scholarly journals Targeting MALAT1 and miRNA-181a-5p for the intervention of acute lung injury/acute respiratory distress syndrome

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Yaling Liu ◽  
Xiaodong Wang ◽  
Peiying Li ◽  
Yanhua Zhao ◽  
Liqun Yang ◽  
...  
Keyword(s):  
Lung Injury ◽  
Vascular Inflammation ◽  
Inflammatory Factors ◽  
Microvascular Endothelial Cell ◽  
High Morbidity ◽  
Therapeutic Effects ◽  
Non Coding Rna ◽  
Pulmonary Microvascular Endothelial Cell ◽  
Long Non Coding Rna

Abstract Background ALI/ARDS is a severe lung injury leading to refractory respiratory failure, accounting for high morbidity and mortality. However, therapeutic approaches are rather limited. Targeting long non-coding RNA MALAT1 and microRNA miR-181a-5p might be potential option for ALI/ARDS intervention. Objective We aimed to investigate the role of MALAT and miR-181a-5p in the pathogenesis of ALI/ARDS, and test the therapeutic effects of targeting MALAT and miR-181a-5p for ALI/ARDS intervention in vitro. Methods MALAT1 and miR-181a-5p levels were measured in plasma from ALI/ARDS patients. In vitro human pulmonary microvascular endothelial cell (HPMEC) injury was induced by LPS treatment, and molecular targets of MALAT1 and miR-181a-5p were explored by molecular biology approaches, mainly focusing on cell apoptosis and vascular inflammation. Interaction between MALAT1 and miR-181a-5p was also detected. Finally, the effects of targeting MALAT1 and miR-181a-5p for ALI/ARDS intervention were validated in a rat ALI/ARDS model. Results MALAT1 upregulation and miR-181a-5p downregulation were observed in ALI/ARDS patients. Transfection of mimic miR-181a-5p into HPMECs revealed decreased Fas and apoptosis, along with reduced inflammatory factors. Fas was proved to be a direct target of miR-181a-5p. Similar effects were also present upon MALAT1 knockdown. As for the interaction between MALAT1 and miR-181a-5p, MALAT1 knockdown increased miR-181a-5p expression. Knocking down of MALAT1 and miR-181a-5p could both improve the outcome in ALI/ARDS rats. Conclusion MALAT1 antagonism or miR-181a-5p could both be potential therapeutic strategies for ALI/ARDS. Mechanistically, miR-181a-5p directly inhibits Fas and apoptosis, along with reduced inflammation. MALAT1 negatively regulates miR-181a-5p.

Sign in / Sign up

Export Citation Format

Share Document